Fosrenol Approval History
- FDA approved: Yes (First approved October 26th, 2004)
- Brand name: Fosrenol
- Generic name: lanthanum carbonate
- Dosage form: Chewable Tablets
- Company: Shire Pharmaceuticals Group plc
- Treatment for: Hyperphosphatemia of Renal Failure
Fosrenol is a phosphate binder used to reduce high phosphorus levels in end-stage renal disease (ESRD) patients.
Development History and FDA Approval Process for Fosrenol
|Oct 26, 2004||Fosrenol Shire Pharmaceuticals Group plc - Treatment for Hyperphosphataemia in ESRD Patients|
|Jul 20, 2004||Fosrenol: FDA Action Date Extended, US Launch Target Unaffected|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.